NASDAQ:XBIT

XBiotech Competitors

$16.64
+0.16 (+0.97 %)
(As of 04/21/2021 12:38 PM ET)
Add
Compare
Today's Range
$16.44
Now: $16.64
$16.68
50-Day Range
$16.68
MA: $18.30
$20.20
52-Week Range
$12.53
Now: $16.64
$21.48
Volume701 shs
Average Volume102,109 shs
Market Capitalization$490.20 million
P/E Ratio1.15
Dividend YieldN/A
Beta1.5

Competitors

XBiotech (NASDAQ:XBIT) Vs. RVNC, AXSM, FGEN, IGMS, KURA, and CYTK

Should you be buying XBIT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to XBiotech, including Revance Therapeutics (RVNC), Axsome Therapeutics (AXSM), FibroGen (FGEN), IGM Biosciences (IGMS), Kura Oncology (KURA), and Cytokinetics (CYTK).

XBiotech (NASDAQ:XBIT) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Earnings and Valuation

This table compares XBiotech and Revance Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XBiotechN/AN/A$668.63 millionN/AN/A
Revance Therapeutics$410,000.004,770.47$-159,430,000.00($3.67)-7.47

XBiotech has higher earnings, but lower revenue than Revance Therapeutics.

Volatility and Risk

XBiotech has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.

Insider and Institutional Ownership

14.8% of XBiotech shares are held by institutional investors. Comparatively, 74.4% of Revance Therapeutics shares are held by institutional investors. 31.0% of XBiotech shares are held by insiders. Comparatively, 4.8% of Revance Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares XBiotech and Revance Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
XBiotechN/A-7.07%-6.67%
Revance Therapeutics-5,818.87%-85.72%-44.85%

Analyst Recommendations

This is a summary of current ratings and target prices for XBiotech and Revance Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
XBiotech0000N/A
Revance Therapeutics00403.00

Revance Therapeutics has a consensus target price of $37.75, suggesting a potential upside of 37.77%. Given Revance Therapeutics' higher probable upside, analysts clearly believe Revance Therapeutics is more favorable than XBiotech.

Summary

XBiotech beats Revance Therapeutics on 7 of the 11 factors compared between the two stocks.

XBiotech (NASDAQ:XBIT) and Axsome Therapeutics (NASDAQ:AXSM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Analyst Recommendations

This is a summary of current ratings and recommmendations for XBiotech and Axsome Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
XBiotech0000N/A
Axsome Therapeutics101002.82

Axsome Therapeutics has a consensus target price of $152.6667, indicating a potential upside of 190.52%. Given Axsome Therapeutics' higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than XBiotech.

Risk and Volatility

XBiotech has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500.

Institutional and Insider Ownership

14.8% of XBiotech shares are held by institutional investors. Comparatively, 63.6% of Axsome Therapeutics shares are held by institutional investors. 31.0% of XBiotech shares are held by insiders. Comparatively, 26.0% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares XBiotech and Axsome Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
XBiotechN/A-7.07%-6.67%
Axsome TherapeuticsN/A-62.33%-47.87%

Earnings and Valuation

This table compares XBiotech and Axsome Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XBiotechN/AN/A$668.63 millionN/AN/A
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-26.53

Summary

XBiotech beats Axsome Therapeutics on 5 of the 9 factors compared between the two stocks.

FibroGen (NASDAQ:FGEN) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of current recommendations and price targets for FibroGen and XBiotech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FibroGen15202.13
XBiotech0000N/A

FibroGen currently has a consensus target price of $45.8333, indicating a potential upside of 128.25%. Given FibroGen's higher possible upside, equities research analysts clearly believe FibroGen is more favorable than XBiotech.

Institutional and Insider Ownership

75.1% of FibroGen shares are owned by institutional investors. Comparatively, 14.8% of XBiotech shares are owned by institutional investors. 3.4% of FibroGen shares are owned by company insiders. Comparatively, 31.0% of XBiotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares FibroGen and XBiotech's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FibroGen$256.58 million7.23$-76,970,000.00($0.89)-22.63
XBiotechN/AN/A$668.63 millionN/AN/A

XBiotech has lower revenue, but higher earnings than FibroGen.

Profitability

This table compares FibroGen and XBiotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FibroGen-191.78%-48.19%-27.72%
XBiotechN/A-7.07%-6.67%

Risk and Volatility

FibroGen has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, XBiotech has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.

Summary

XBiotech beats FibroGen on 6 of the 11 factors compared between the two stocks.

IGM Biosciences (NASDAQ:IGMS) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.

Volatility & Risk

IGM Biosciences has a beta of -1.12, suggesting that its share price is 212% less volatile than the S&P 500. Comparatively, XBiotech has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for IGM Biosciences and XBiotech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IGM Biosciences01602.86
XBiotech0000N/A

IGM Biosciences currently has a consensus price target of $98.8750, suggesting a potential upside of 70.65%. Given IGM Biosciences' higher probable upside, analysts plainly believe IGM Biosciences is more favorable than XBiotech.

Profitability

This table compares IGM Biosciences and XBiotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IGM BiosciencesN/A-33.30%-30.28%
XBiotechN/A-7.07%-6.67%

Institutional & Insider Ownership

47.6% of IGM Biosciences shares are owned by institutional investors. Comparatively, 14.8% of XBiotech shares are owned by institutional investors. 79.3% of IGM Biosciences shares are owned by insiders. Comparatively, 31.0% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares IGM Biosciences and XBiotech's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-12.07
XBiotechN/AN/A$668.63 millionN/AN/A

Summary

XBiotech beats IGM Biosciences on 5 of the 9 factors compared between the two stocks.

XBiotech (NASDAQ:XBIT) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for XBiotech and Kura Oncology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
XBiotech0000N/A
Kura Oncology011002.91

Kura Oncology has a consensus price target of $39.5455, indicating a potential upside of 43.07%. Given Kura Oncology's higher possible upside, analysts clearly believe Kura Oncology is more favorable than XBiotech.

Earnings & Valuation

This table compares XBiotech and Kura Oncology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XBiotechN/AN/A$668.63 millionN/AN/A
Kura OncologyN/AN/A$-63,140,000.00($1.51)-18.30

Volatility & Risk

XBiotech has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500.

Institutional and Insider Ownership

14.8% of XBiotech shares are owned by institutional investors. Comparatively, 94.7% of Kura Oncology shares are owned by institutional investors. 31.0% of XBiotech shares are owned by insiders. Comparatively, 11.0% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares XBiotech and Kura Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
XBiotechN/A-7.07%-6.67%
Kura OncologyN/A-30.96%-28.02%

Summary

XBiotech beats Kura Oncology on 5 of the 9 factors compared between the two stocks.

XBiotech (NASDAQ:XBIT) and Cytokinetics (NASDAQ:CYTK) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Profitability

This table compares XBiotech and Cytokinetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
XBiotechN/A-7.07%-6.67%
Cytokinetics-209.88%-3,065.14%-36.39%

Volatility and Risk

XBiotech has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500.

Institutional & Insider Ownership

14.8% of XBiotech shares are owned by institutional investors. Comparatively, 97.1% of Cytokinetics shares are owned by institutional investors. 31.0% of XBiotech shares are owned by insiders. Comparatively, 6.4% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares XBiotech and Cytokinetics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XBiotechN/AN/A$668.63 millionN/AN/A
Cytokinetics$26.87 million66.96$-121,690,000.00($2.11)-11.92

XBiotech has higher earnings, but lower revenue than Cytokinetics.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for XBiotech and Cytokinetics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
XBiotech0000N/A
Cytokinetics011002.91

Cytokinetics has a consensus target price of $34.6364, suggesting a potential upside of 37.77%. Given Cytokinetics' higher probable upside, analysts plainly believe Cytokinetics is more favorable than XBiotech.

Summary

XBiotech beats Cytokinetics on 7 of the 11 factors compared between the two stocks.


XBiotech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.40+2.2%$1.91 billion$410,000.00-5.96
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.32+5.0%$1.89 billionN/A-19.82Unusual Options Activity
News Coverage
FibroGen logo
FGEN
FibroGen
1.8$20.14+1.0%$1.87 billion$256.58 million-7.72
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$57.94+0.1%$1.86 billionN/A-24.66
Kura Oncology logo
KURA
Kura Oncology
1.6$27.64+1.1%$1.85 billionN/A-16.96News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$25.15+0.6%$1.81 billion$26.87 million-13.17Analyst Report
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$19.87+1.4%$1.79 billion$34.51 million-16.98
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05+0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00+0.0%$1.77 billion$14.87 million-14.18
MORF
Morphic
1.3$57.34+5.4%$1.76 billion$16.98 million-36.76Insider Selling
Gap Up
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.74+0.7%$1.72 billion$428.41 million15.57Analyst Upgrade
Unusual Options Activity
News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.71+0.7%$1.70 billion$1.63 billion13.93
Generation Bio logo
GBIO
Generation Bio
1.8$30.49+1.3%$1.70 billionN/A0.00Gap Up
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.86+0.4%$1.63 billion$145.97 million-7.23
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.49+2.5%$1.62 billion$392.76 million13.07Analyst Upgrade
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.88+5.4%$1.62 billionN/A-6.72Analyst Downgrade
Increase in Short Interest
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.24+1.2%$1.58 billion$2.34 million-9.85
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$27.82+1.4%$1.56 billionN/A0.00
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.5$35.75+7.1%$1.55 billionN/A0.00Analyst Upgrade
News Coverage
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.60+1.5%$1.52 billion$175.34 million-15.06Insider Selling
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.16+2.4%$1.51 billion$320,000.00-8.27
uniQure logo
QURE
uniQure
1.7$31.81+2.2%$1.46 billion$7.28 million-8.44Unusual Options Activity
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.45+1.7%$1.46 billion$82.27 million-18.17
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$29.65+3.3%$1.44 billionN/A-3.21Analyst Upgrade
Gap Up
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$61.95+1.1%$1.43 billionN/A0.00
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$22.22+0.6%$1.42 billion$73.41 million-4.70News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$40.59+2.0%$1.40 billionN/A0.00
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.02+2.4%$1.40 billionN/A0.00Gap Down
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$31.89+0.5%$1.38 billion$6.20 million-13.99
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.02+1.9%$1.37 billion$19.89 million-13.22
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$27.56+4.0%$1.37 billion$4.23 million-20.41Analyst Report
Increase in Short Interest
News Coverage
Gap Down
OLMA
Olema Pharmaceuticals
1.6$34.92+3.9%$1.35 billionN/A0.00Gap Up
Endo International logo
ENDP
Endo International
1.5$5.74+1.9%$1.30 billion$2.91 billion-8.44
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.41+6.6%$1.28 billionN/A-143.38Analyst Downgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$29.51+0.0%$1.23 billionN/A0.00Analyst Report
Insider Selling
Zymeworks logo
ZYME
Zymeworks
1.8$27.25+2.8%$1.22 billion$29.54 million-7.23News Coverage
Innoviva logo
INVA
Innoviva
1.4$12.03+0.4%$1.21 billion$261.02 million6.14News Coverage
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$32.81+1.6%$1.18 billionN/A0.00Analyst Upgrade
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$31.25+2.2%$1.18 billionN/A0.00Analyst Report
Insider Selling
Gap Up
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$27.45+3.0%$1.17 billion$230,000.00-12.77
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.91+4.5%$1.16 billion$59.70 million-199.10
Omeros logo
OMER
Omeros
1.2$19.12+3.0%$1.15 billion$111.81 million-8.03
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.81+1.1%$1.14 billionN/A-17.12
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.09+0.1%$1.14 billionN/A-8.78Analyst Report
Increase in Short Interest
News Coverage
Kronos Bio logo
KRON
Kronos Bio
1.7$21.06+4.7%$1.13 billionN/A0.00Insider Selling
News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.24+3.0%$1.12 billion$4.23 million-8.51
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$36.82+3.9%$1.11 billionN/A-2.63
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.12+0.1%$1.10 billionN/A-6.80Upcoming Earnings
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$16.07+1.1%$1.10 billion$42.12 million-11.90
MannKind logo
MNKD
MannKind
1.4$4.50+6.0%$1.05 billion$63.04 million-21.43Increase in Short Interest
News Coverage
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.